OGT signs deal for commercialization of colorectal cancer biomarker test
Oxford Gene Technology announced that it has entered into an exclusive licensing agreement with Inven2, the University of Oslo, and the technology transfer office at Oslo University, for 12 promising colorectal cancer tissue biomarkers. Colorectal cancer is the second most common cancer in women, and the 3rd most common cancer in men. The prognosis for patients is much improved if this form of cancer is detected at an early stage. Early detection and prevention of colorectal cancer through screening has caused an unprecedented reduction in incidence and death rates.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063